As of Aug 26
| +0.09 / +0.52%|
The 6 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 19.50, with a high estimate of 25.00 and a low estimate of 18.00. The median estimate represents a +11.88% increase from the last price of 17.43.
The current consensus among 7 polled investment analysts is to Buy stock in Nektar Therapeutics. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.